Physician profile
Scott Whitlock
NPI 1992237473
$6,699.82
in general payments reported to CMS, 2019-2025
13 companies · $362 in 2025
The $362 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $35.56 · 2021: $34.93 · 2022: $5,503 · 2024: $765 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,126.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,318.34 | 2022-2025 | |
| Abbvie INC. | $455.72 | 2020-2025 | |
| Ucb, INC. | $223.65 | 2024-2025 | Bimzelx |
| Amgen INC. | $157.45 | 2024 | Otezla |
| Lilly USA, LLC | $124.97 | 2024-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $102.48 | 2024-2025 | |
| Pfizer INC. | $99.00 | 2022 | |
| Janssen Biotech, INC. | $78.46 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $60.09 | 2025 | Dupixent, Libtayo |
| Strata Skin Sciences, INC. | $22.85 | 2025 | Xtrac |
| Hill Dermaceuticals, INC. | $22.20 | 2025 | Tolak |
| Incyte Corporation | $17.98 | 2024 | Opzelura |
| Genentech USA, INC. | $16.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Whitlock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.